Mereo BioPharma Group Plc (MREO)
0.3499
-0.03
(-6.74%)
USD |
NASDAQ |
Oct 09, 16:00
0.3583
+0.01
(+2.40%)
Pre-Market: 09:26
Mereo BioPharma Group Free Cash Flow (Quarterly) : -6.049M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.049M |
| March 31, 2026 | -4.604M |
| December 31, 2025 | -7.670M |
| September 30, 2025 | -7.254M |
| June 30, 2025 | -7.758M |
| Date | Value |
|---|---|
| March 31, 2025 | -8.682M |
| December 31, 2024 | -9.326M |
| September 30, 2024 | -7.622M |
| June 30, 2024 | -7.913M |
| March 31, 2024 | -8.686M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -2.616M |
| BioNTech SE | -52.17M |
| Silence Therapeutics Plc | 1.548M |
| Autolus Therapeutics Plc | -26.08M |